Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
The Lancet. Haematology|March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trialEytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialStefan Faderl, Meir Wetzler, David Rizzieri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344Carrie M Brodmerkel, Reid Huber, Maryanne Covington, et al.The Lancet. Oncology|March 13, 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2010
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050Jordan S Fridman, Peggy A Scherle, Robert Collins, et al.Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.Journal of Medicinal Chemistry|May 27, 2026
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune DiseasesJincong Zhuo, Yun-Long Li, Ding-Quan Qian, et al.Nature Communications|January 18, 2019
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsHaijiao Zhang, Samantha Savage, Anna Reister Schultz, et al.Blood|June 8, 2017
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.Pageof 7